bendroflumethiazide indications/contra

Stem definitionDrug idCAS RN
diuretics, chlorothiazide derivatives 305 73-48-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bendroflumethiazide
  • bendrofluazide
  • benzhydroflumethiazide
  • benzidroflumetiazide
  • benzydroflumethiazide
  • benzylhydroflumethiazide
  • benzylrodiuran
A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
  • Molecular weight: 421.41
  • Formula: C15H14F3N3O4S2
  • CLOGP: 1.73
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 118.36
  • ALOGS: -3.29
  • ROTB: 4

Drug dosage:

DoseUnitRoute
2.50 mg O
2.50 mg O

Approvals:

DateAgencyCompanyOrphan
Dec. 7, 1959 FDA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 939.69 75.58 184 419 18175 3367081
Acute kidney injury 370.04 75.58 106 497 49577 3335679
Confusional state 249.52 75.58 74 529 37924 3347332
Dehydration 183.51 75.58 57 546 33592 3351664
Hypokalaemia 178.45 75.58 46 557 13759 3371497
Hypotension 173.56 75.58 60 543 49454 3335802
Vomiting 149.05 75.58 63 540 89468 3295788
Hypophagia 127.77 75.58 30 573 6031 3379225
Fall 112.84 75.58 46 557 58837 3326419
Drug interaction 104.95 75.58 41 562 46771 3338485
Diarrhoea 102.35 75.58 51 552 104297 3280959
Hypomagnesaemia 86.75 75.58 20 583 3682 3381574
Delirium 85.75 75.58 24 579 9604 3375652
Monoclonal B-cell lymphocytosis 77.07 75.58 9 594 15 3385241

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC C03AA01 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides, plain
ATC C03AB01 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides and potassium in combination
ATC C03EA13 CARDIOVASCULAR SYSTEM
DIURETICS
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
Low-ceiling diuretics and potassium-sparing agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D049993 Sodium Chloride Symporter Inhibitors
CHEBI has role CHEBI:35498 diuretic
CHEBI has role CHEBI:35674 antihypertensive agent
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175419 Thiazide Diuretic
FDA Chemical/Ingredient N0000166469 Thiazides

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Hypercholesterolemia contraindication 13644009
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007 DOID:2848
Hyperuricemia contraindication 35885006 DOID:1920
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:2527
Myasthenia gravis contraindication 91637004 DOID:437
Hypomagnesemia contraindication 190855004
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Right ventricular failure contraindication 367363000

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.79 acidic
pKa2 10.52 acidic
pKa3 1.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR A2 8.30 WOMBAT-PK CHEMBL
Calcium-activated potassium channel subunit alpha-1 Ion channel WOMBAT-PK
Carbonic anhydrase 4 Enzyme WOMBAT-PK
Carbonic anhydrase 1 Enzyme WOMBAT-PK
Carbonic anhydrase 2 Enzyme WOMBAT-PK

External reference:

scroll-->
IDSource
DB00436 DRUGBANK_ID
4017612 VUID
N0000145992 NUI
C0004975 UMLSCUI
7122 IUPHAR_LIGAND_ID
D00650 KEGG_DRUG
5Q52X6ICJI UNII
994 INN_ID
4017612 VANDF
N0000005797 NDFRT
N0000145992 NDFRT
3020 MMSL
1369 RXNORM
387520007 SNOMEDCT_US
91135008 SNOMEDCT_US
4252 MMSL
d00641 MMSL
002297 NDDF
2315 PUBCHEM_CID
CHEMBL1684 ChEMBL_ID
D001539 MESH_DESCRIPTOR_UI
CHEBI:3013 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5311 TABLET 5 mg ORAL ANDA 12 sections
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5322 TABLET 5 mg ORAL ANDA 12 sections
CORZIDE HUMAN PRESCRIPTION DRUG LABEL 2 60793-283 TABLET 5 mg ORAL NDA 12 sections
CORZIDE HUMAN PRESCRIPTION DRUG LABEL 2 60793-284 TABLET 5 mg ORAL NDA 12 sections